Skip to main content Skip to main navigation menu Skip to site footer
Subscription Contact the editors
  • en
  • ru
REMEDIUM
ISSN 1561-5936 (Print)
ISSN 2658-3534 (Online)
  • Current
  • Archive
  • About
    • About the Journal
    • Author Guidelines
    • Editorial Masthead
    • Privacy Statement
  • Editorial Board
  • Contact
  • Register
  • Login
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

Found one item.
  • Comparative analysis of business models of top pharmaceutical manufacturing companies: financial analysis

    Yasinskaya L.E.
    43-52
    2020-12-15
    Abstract
    Introduction. Earlier, the comparative analysis of the commercial and investment activities of the companies that play the key roles in the investment processes in the Russian pharmaceutical industry and operate within the four main business models (biotechnological, generic, specialized pharmaceutical companies, active pharmaceutical ingredient (API) manufacturers) has been conducted. No full assessment of the companies’ activities is conceivable without a financial analysis of their activities to identify the risks of investment activities.Objective of the study. A detailed comparative analysis of the financial standing of domestic pharmaceutical manufacturers operating within the selected business models for further identification of potential financial risks for investors. Research procedure and article structure. Analysis of RAS statements (forms 1 and 2) of 72 over 500 million revenue companies grouped together as selectedbusiness models for the period from 2015 to 2019.Results. The researchers provided a detailed description of the commercial activities of domestic pharmaceutical companies within the business models under consideration. The companies within various business models showed positive revenue growth rates over the past five years. All business models demonstrate consistently high business profitability and a significant share of own capital in the asset profile.Conclusion. The results of the study show the stable financial standing of the pharmaceutical companies within various business models. The biotechnology sector companies that are the most attractive for investments have the highest quality financial standing. The specialized and generic companies show similar consistently strong performance. API manufacturers that the companies with relatively small revenues are actively developing and are attractive to restrained budget investors.
1 - 1 of 1 items

Главный редактор

Editor-in-chief

 

 

Khabriev Ramil

Make a Submission

Make a Submission

Information

  • For Readers
  • For Authors
  • For Librarians

Latest publications

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Mailing address

Адрес: 105064, г. Москва, ул. Воронцово Поле, д. 12, стр. 1

Email: redactor@remedium-journal.ru

Телефон: +7(495) 917-48-86

Editorial office

Шерстнева Елена Владимировна
FSSBI «N.A. Semashko National Research Institute of Public Health»

E-mail:

© 2026 Journal «REMEDIUM»